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INTRODUCTION
An obligate step in the retroviral replication cycle is the integration 
of the viral reverse transcript into a chromosome of the infected 
cell, a trait that makes retrovirus-based vectors particularly useful 
for gene therapy applications.1 However, the benefits of efficient 
and stable gene delivery by retroviral vectors may be outweighed 
by risk of genotoxic effects, which include mutagenesis from vector 
insertion in the vicinity of proto-oncogenes. The recent successes 
and misfortunes of gene therapy trials call out for technologies to 
exert control over the specificity of retroviral DNA integration.2
Control of integration specificity has been approached through 
the modification of key viral and host cell proteins. Integration is 
catalyzed by the viral integrase (IN), which enters the cell as a 
virion component and associates with the viral DNA as it mobi-
lizes to a suitable chromosomal acceptor site for integration.3 
Heterologous polydactyl zinc finger proteins fused to Moloney 
murine leukemia virus or human immunodeficiency virus type 
1 (HIV-1) IN can alter integration specificity, though associated 
10- to 104-fold losses in vector titer may limit their practical 
application.4,5 The family Retroviridae comprises seven genera 
(α through ε, spuma, and lenti), and the different viruses select 
for different chromatin features during integration. As examples, 
γ-retroviruses such as Moloney murine leukemia virus target the 
promoter regions of genes, while lentiviruses, which include 
HIV-1, favor the bodies of active genes.6 These specificities are 
largely attributable to IN-binding host factors BET (for bromo-
domain and extraterminal domain) proteins for Moloney murine 
leukemia virus7,8 and lens epithelium–derived growth factor 
(LEDGF)/p75 for HIV-1.9–11 LEDGF/p75 harbors modular protein 
domains that include an N-terminal PWWP chromatin-binding 
domain (CBD)12,13 and a downstream IN-binding domain (IBD).14 
Constructs containing heterologous CBDs fused to the LEDGF/
p75 IBD redirect HIV-1 integration to sites predictably bound by 
the CBD15–17 and concordantly form the basis of the novel HIT-Seq 
(HIV integration targeting) genomic footprinting technique.18 
Despite their promise, the potential clinical use of such heterolo-
gous fusion constructs is complicated by the ubiquitous expres-
sion and high copy number of endogenous LEDGF/p75 pro-
tein.11,19,20 To address this limitation, we previously reengineered 
the electrostatic portion of the HIV-1 IN-LEDGF/p75 binding 
interface to generate compatible variants of the two proteins, 
such that defective IN mutant proteins and viruses supported 
~45% of the level of wild-type (WT) IN-LEDGF/p75 binding and 
~13% of WT HIV-1 infection when presented with the reverse-
charge LEDGF/p75 partner.21 The goal of the present study was 
to increase the efficiency of IN mutant viral transduction in the 
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Controlling the specificity of retroviral DNA integration could improve the safety of gene therapy vectors, and fusions of het-
erologous chromatin binding modules to the integrase (IN)–binding domain from the lentiviral integration host cofactor lens 
epithelium–derived growth factor (LEDGF)/p75 are a promising retargeting strategy. We previously proposed the utility of IN 
mutant lentiviral vectors that are selectively activated by complementary LEDGF/p75 variants, and our initial modifications 
in human immunodeficiency virus type 1 IN and LEDGF/p75 supported about 13% of wild-type vector transduction activity. 
Here we describe the selection and characterization of the K42E gain-of-function mutation in IN, which greatly improves the 
efficiency of this system. Both K42E and initial reverse-charge mutations in IN negatively affected reverse transcription and 
integration, yet when combined together boosted viral transduction efficiency to ~75% of the wild-type vector in a manner 
dependent on a complementary LEDGF/p75 variant. Although the K42E mutation conferred functional gains to IN mutant 
viral reverse transcription and integration, only the integration boost depended on the engineered LEDGF/p75 mutant. We 
conclude that the specificity of lentiviral retargeting strategies based on heterologous LEDGF/p75 fusion proteins will benefit 
from our optimized system that utilizes the unique complementation properties of reverse-charge IN mutant viral and LEDGF/
p75 host proteins.
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face of reverse-charge LEDGF/p75 mutant proteins. Using virus 
evolution, we selected for the novel K42E mutation in IN that 
increased the efficiency of the customized transduction system 
to ~75% of the level of WT HIV-1.
ReSUlTS
Experimental strategy
The details of the IN-LEDGF/p75 interaction have been elu-
cidated using structural biology approaches.22 IN comprises 
three domains: the N-terminal domain (NTD), catalytic core 
domain (CCD), and C-terminal domain.23 The CCD harbors the 
primary LEDGF/p75 binding determinant, while the NTD addi-
tionally contributes to the high affinity interaction.21,24,25 LEDGF/
p75 hotspot residue Asp366 engages the loop connecting CCD 
α helices 4 and 5 (referred to as the α4/5 connector),25,26 while 
LEDGF/p75 electropositive residues Lys401, Lys402, and Arg405 
engage electronegative residues at IN NTD positions 6, 10, and 
1321 (Figure 1a).
LEDGF/p75 mutants are assessed for their ability to support HIV-1 
infection using cells that are depleted of the endogenous host fac-
tor through genetic knockout10,13 or RNA-mediated knockdown.27,28 
We previously established methods to transduce transiently trans-
fected mouse embryo fibroblast (MEF) knockout cells with single-
round HIV-Luc particles that carry the vesicular stomatitis virus G 
(VSV-G) glycoprotein for entry into mouse cells and the luciferase 
reporter gene.10,13 Alteration of LEDGF/p75 residues Lys401, Lys402, 
and Arg405 to glutamates (K401E/K402E/R405E, referred to as EEE) 
reduced WT HIV-Luc infection by approximately fivefold, yet boosted 
the activity of the weakly infectious reverse-charge KK (E10K/E13K) 
HIV-1 IN mutant virus by approximately sixfold (from ~2% with WT 
LEDGF/p75 to ~13% with EEE).21 Because the reverse-charge IBD 
and HIV-1 IN mutant proteins interacted in a yeast two-hybrid assay 
at 45% of the efficiency of the WT pair,21 we reasoned that trans-
duction of LEDGF/p75 EEE-expressing MEFs by the IN KK mutant 
virus was limited by factors specific to the cell-based experiment. 
Our strategy to investigate this bottleneck to mutant viral infection 
was to select for the outgrowth of viruses with improved fitness 
over multiple rounds of replication. Several aspects of experimental 
design required optimization before embarking on the virus evo-
lution experiment. Because the KK mutant virus differed from WT 
HIV-1 at only two nucleotide positions, it could reasonably revert 
back to the WT sequence over several rounds of replication. IN 
mutants that carried additional nucleotide changes were, therefore, 
tested alongside the KK mutant for transduction of WT versus EEE 
LEDGF/p75-expressing MEFs. As reported,21 the transduction effi-
ciency of the IN KK mutant virus increased approximately sixfold 
from expressing EEE compared with WT LEDGF/p75 (Figure  1b). 
Similar differential transduction levels were observed for each of 
the novel mutant viruses; as RR (E10R/E13R) and KR (E10K/E13R) 
would require six and four nucleotide changes, respectively, to 
revert to the WT sequence, they were earmarked for virus evolution. 
Mutagenesis was also used to optimize the reverse-charge LEDGF/
p75 partner. To address if the electropositive Arg404 residue might 
interact intramolecularly with the electronegative mutant side 
chains in EEE (Figure 1a) and potentially interfere with mutant pro-
tein function, it was mutated to Leu in the context of EEE to yield 
EELE, or in the context of QEE (K401Q/K402E/R405E) to yield QELE. 
The KK mutant virus similarly transduced cells expressing EE (K402E/
K405E), EEE, EELE, or QELE mutant LEDGF/p75 protein (Figure 1c). 
Because position 404 alterations did not detectably improve mutant 
LEDGF/p75 function, EEE was chosen for virus evolution.
Although mouse cells are efficiently transduced with appropri-
ately pseudotyped HIV-1 particles, they do not support spreading 
virus replication.29 To circumvent this limitation, TL3 cells, which 
were derived from CD4-positive SupT1 T cells,27 were used for virus 
Figure 1.  The IN NTD-LEDGF/p75 interaction and IN mutant viral and LEDGF/p75 protein activities. (a) Details of the HIV-2 IN NTD-IBD interface (chains 
A, B, and C from protein database code 3f9k). IN is shown in cyan, with the oxygen atoms of interacting Glu residues in red. The LEDGF/p75 IBD is in 
green, with the nitrogen atoms of Lys401, Lys402, Arg404, and Arg405 in blue. Salt bridge interactions between side chains are indicated by dashed 
line21 (b) The infectivities of the indicated IN-mutant viruses were normalized to WT HIV-Luc in WT LEDGF/p75–expressing cells. The inset shows levels 
of WT and EEE LEDGF/p75 proteins in transfected cells following cell sorting; β-actin was monitored to control for sample loading. Two-letter codes 
refer to substitutions at positions 10 and 13 in HIV-1 IN. NKK, D6N/E10K/E13K. (c) E10K/E13K IN mutant viral infectivity in the presence of the indicated 
LEDGF/p75 protein was normalized to WT HIV-Luc infection of WT LEDGF/p75-expressing cells. Panel b and c results are averages of two and three 
independent experiments, respectively, ± SD. *P < 0.05 as determined by one-tail t-test; **P < 0.01. P > 0.05 are indicated in parentheses. EEE, K401E/
K402E/R405E; HIV-1, human immunodeficiency virus type 1; IBD, IN-binding domain; IN, integrase; LEDGF, lens epithelium–derived growth factor; NTD, 
N-terminal domain; WT, wild type.
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evolution. The level of endogenous LEDGF/p75 protein in TL3 cells is 
suppressed through the expression of short hairpin (sh) RNA,27 and 
the cells concordantly support ~3–15% of the level of HIV-Luc trans-
duction compared with LEDGF/p75-expressing control cells.27,28,30 
TL3 cells were transduced with puromycin-selectable retroviral vec-
tors that expressed shRNA-resistant WT or EEE LEDGF/p75 fused to 
a hemagglutinin (HA) tag to monitor ectopic protein levels. Single-
cell clones expressed WT and EEE HA-LEDGF/p75 proteins at levels 
similar to the level of endogenous LEDGF/p75 in parental SupT1 
cells as assessed by blotting with anti-LEDGF/p75 and anti-HA anti-
bodies (Figure 2a). Fluorescence-activated cell sorting was used to 
monitor percentages of CD4-positive cells; WT and EEE cells were 
88 and 95% positive, respectively, which was similar to parental TL3 
and SupT1 cells (95 and 92%, respectively). SupT1 and WT cells sup-
ported similar levels of HIV-Luc transduction, which were approxi-
mately two- to threefold greater than the levels supported by TL3 
and EEE cells (Figure 2b). Although this level of infection defect for 
TL3 cells is somewhat milder than that reported previously, a ~27-
fold defect was observed in an independent set of experiments 
(see below). Importantly, transduction by the IN KR mutant virus 
was stimulated approximately fivefold by expressing EEE compared 
with WT LEDGF/p75 (Figure 2c).
Selection of reverse-charge IN mutant viruses with improved 
replicative fitness
WT, EEE, and TL3 cells were infected with replication-competent 
HIV-1NL4-3 carrying WT, KR, or RR IN at a multiplicity of infection of 
~0.1,31 and culture supernatants were monitored for evidence of 
virus replication over 60 days. TL3 and EEE cells supported peak 
WT HIV-1 replication 9 days postinfection, whereas WT LEDGF/
p75 expression accelerated virus growth to yield a peak at 7 days 
(Figure  3a–c). HIV-1 IN mutant viral growth depended on EEE 
LEDGF/p75 expression; under these conditions, the peaks of KR 
and RR replication appeared 35 and 46 days postinfection, respec-
tively (Figure 3c). Fresh EEE cells were infected with viruses har-
vested from these peaks (e1KR and e1RR) alongside WT HIV-1NL4-3. 
Both e1KR and e1RR grew with significantly accelerated kinetics 
compared with their parental KR and RR molecular clones (com-
pare Figure 3d with Figure 3c). Viruses e2KR and e2RR harvested 
from e1KR and e1RR replication peaks were passaged alongside WT 
HIV-1NL4-3 onto fresh EEE and WT cells. EEE cells supported mutant 
viral growth delayed by only 2 days from WT HIV-1NL4-3; by contrast, 
the growth of the passaged mutant viruses was delayed from the 
WT virus by 17 days in WT LEDGF/p75-expressing cells (Figure 3e). 
Mutant viral genomes were amplified from EEE-infected cells at the 
peaks of e2KR and e2RR replication. The sequencing of overlapping 
PCR products that covered the entire genomes with the exception 
of the env gene in both cases revealed a single nucleotide A to G 
change at position 4353 in pol, which corresponded to the substitu-
tion of Glu for Lys42 (K42E) in the NTD of IN.
Two new molecular clones were made by introducing the K42E 
mutation into KR and RR HIV-1NL4-3, yielding KRE and RRE, respec-
tively. KRE and RRE grew in WT and EEE cells with kinetics that were 
virtually indistinguishable (delayed by at most 2 days) from seri-
ally passed e2KR and e2RR supernatants (denoted e3KR and e3RR, 
respectively, in Figure 4a,b). From these data, we conclude that the 
K42E mutation is primarily if not solely responsible for the observed 
increase in replication fitness of the KR and RR IN mutant viruses in 
EEE-expressing cells. To address if the K42E gain-of-function pheno-
type was observed during the early stage of HIV-1 replication that 
includes integration, the mutation was introduced into WT and RR 
single-round constructs, and knockout MEFs expressing WT, EEE, or 
E4 (EEE with an added K360E change)21 LEDGF/p75 were infected 
with WT, RR, K42E, and RRE HIV-Luc. EEE and E4 enhanced RR HIV-Luc 
infectivity by approximately six- and fourfold, respectively, com-
pared with WT LEDGF/p75 (Figure 4c). The K42E mutation interest-
ingly reduced HIV-Luc transduction of WT LEDGF/p75-expressing 
cells by ~10-fold, and in the absence of other IN changes did not 
confer any obvious preference for EEE or E4 LEDGF/p75. Infection 
of EEE LEDGF/p75-expressing cells by the RR HIV-Luc mutant virus 
was by contrast boosted approximately threefold by the K42E muta-
tion, such that RRE attained 75% of the level of WT HIV-Luc infectiv-
ity on cells expressing WT LEDGF/p75 (Figure 4c). We note that the 
K42E mutation also boosted the infectivity of the RR mutant virus in 
the face of WT LEDGF/p75, from about 4% without the mutation to 
about 24% in its presence (Figure 4c).
Biochemical analysis of recombinant protein binding and IN strand 
transfer activity
The results presented in Figure 4c show that the K42E mutation 
conferred gain-of-function to the RR mutant virus but not to WT 
HIV-1 under conditions that required integration and expression 
of the luciferase reporter gene. To test the contribution of the K42E 
change to WT and RR IN protein function, the K42E, RR, and RRE 
Figure 2.  Construction and characterization of WT LEDGF/p75 and mutant EEE-expressing T cells. (a) Levels of endogenous (lanes 1 and 2) and 
ectopically expressed (lanes 3 and 4) LEDGF/p75 as assessed by immunoblotting. (b) Levels of HIV-Luc infectivity with the indicated cells, normalized 
to the level observed with the WT LEDGF/p75-expressing cells. (c) Infectivity of HIV-Luc bearing KR IN mutations with the indicated cells, normalized to 
the level observed with EEE-expressing cells. Panel b and c results are averages of two independent experiments ± SD. *P < 0.05; **P < 0.01. EEE, K401E/
K402E/R405E; IN, integrase; KR, E10K/E13R; LEDGF, lens epithelium–derived growth factor; WT, wild type.
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mutations were engineered into a hexahistidine (His6)-tagged IN 
expression construct, and proteins purified following their expres-
sion in bacteria were tested in in vitro LEDGF/p75 binding and IN 
activity assays. Binding of IN-His6 to WT and EEE LEDGF/p75 was 
determined using a Ni2+-nitrilotriacetic acid pull-down assay.21 The 
K42E mutation reduced WT LEDGF/p75 binding by approximately 
twofold, whereas neither RR nor RRE IN bound a detectable level of 
WT LEDGF/p75 ( Figure 5a, lanes 1–11; quantified in Figure 5b). As 
reported,21 WT IN did not detectably bind EEE LEDGF/p75 protein. 
Compared with the level of WT LEDGF/p75 protein bound by WT IN, 
K42E, RR, and RRE IN bound EEE LEDGF/p75 protein at ~42, 11, and 
15% efficiency, respectively (Figure 5a, lanes 12–16, and Figure 5b).
Figure 3.  Replication kinetics of WT and IN mutant HIV-1NL4-3 in T-cell lines. Parental (a) TL3 cells or (b) WT or (c) EEE LEDGF/p75-expressing subclones 
were infected with replication-competent WT, KR, or RR virus, and reverse transcriptase (RT) activity in cell supernatants was measured at the indicated 
time points. (d) Viruses harvested from EEE-expressing cells in panel c at the peaks of KR and RR replication (e1KR and e1RR, respectively) were passed 
onto fresh EEE cells, and RT values were measured every 3 or 4 days. (e) Viruses e2KR and e2RR collected from panel d replication peaks were passed 
onto fresh WT and EEE-expressing cells. RT values are indicated. Dpi, days postinfection; EEE, K401E/K402E/R405E; HIV-1, human immunodeficiency 
virus type 1; KR, E10K/E13R; LEDGF, lens epithelium–derived growth factor; RR, E10R/E13R; WT, wild type.
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Figure 4.  The K42E mutation accounts for the improved replication fitness of KR and RR mutant viruses. (a) TL3 cells expressing WT LEDGF/p75 were 
infected with WT, KRE, or RRE HIV-1NL4-3 alongside e3KR and e3RR supernatants harvested from replication peaks in panel e from Figure 3. Reverse 
transcriptase activity was determined at the indicated time points. (b) Same as in panel a, except that EEE cells were infected. (c) WT, K42E, RR, and RRE 
HIV-Luc transduction of knockout MEFs transfected with the indicated empty or WT, EEE, or E4 LEDGF/p75 expression vector. Infectivity of WT HIV-Luc 
in the presence of WT LEDGF/p75 was set to 100%; other values are mean ± SD for n = 2 independent experiments. Statistical comparisons of RR versus 
RRE viruses on cells expressing WT and EEE LEDGF/p75 are indicated. **P < 0.01. EEE, K401E/K402E/R405E; HIV-1, human immunodeficiency virus type 
1; KR, E10K/E13R; LEDGF, lens epithelium–derived growth factor; MEF, mouse embryo fibroblast; RR, E10R/E13R; WT, wild type.
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IN strand transfer activity was assayed using an oligonucle-
otide substrate that modeled the U5 end of HIV-1 DNA and a 
circular plasmid DNA target. Mimicking its function during virus 
infection, recombinant IN can integrate a pair of oligonucleotide 
substrates into opposing strands of target DNA with a 5-bp spac-
ing, which after deproteination yields a linear concerted DNA 
recombination product.21 For reasons that are not entirely clear, 
HIV-1 IN yields substantial half-site integration products in vitro, 
which result from a failure to either engage or integrate a sec-
ond molecule of substrate oligonucleotide. In agarose gels, such 
half-site products comigrate with the open circular form of the 
target DNA plasmid isolated from Escherichia coli. In the absence 
of LEDGF/p75, IN displayed a basal level of half-site strand trans-
fer activity (Figure 5c, lanes 1–5). The addition of LEDGF/p75 sig-
nificantly stimulated IN half-site and concerted strand transfer 
activities (compare lane 6 with lane 2 in Figure 5c).21 Because 
the concerted integration product becomes retargeted by half-
site integration events, we note its migration varies depending 
on the overall level of strand transfer activity. K42E, RR, and RRE 
INs supported about 83, 53, and 18% of the level of WT IN con-
certed integration activity in the presence of WT LEDGF/p75 
(Figure 5c, lanes 6–9; quantified in Figure 5d). EEE LEDGF/p75 
stimulated about 17% of WT IN concerted integration activity, 
though it failed to appreciably stimulate the K42E IN mutant pro-
tein (Figure 5c, lanes 10 and 11). The mutant integration cofactor 
stimulated RR and RRE concerted integration activities to ~55 
and 78% of the levels observed for WT IN with WT LEDGF/p75 
(Figure 5c,d).
Stimulation of IN mutant viral DNA synthesis and integration by 
the K42E mutation
Although our biochemical analysis revealed a gain-of-function for 
RR IN from the K42E mutation in the presence of LEDGF/p75 EEE 
protein, the magnitude of the differential strand transfer activity 
effect appeared less than that observed during virus infection (com-
pare Figures 5d and 4c). The K42E change moreover only margin-
ally reduced WT LEDGF/p75-dependent IN strand transfer activity 
(Figure 5d), yet reduced HIV-Luc infectivity by ~10-fold (Figure 4c). 
To further investigate the molecular bases for the viral infection 
phenotypes, reverse transcription and integration were analyzed 
by quantitative PCR using single-round WT, RR, K42E, and RRE HIV-
Luc viruses and TL3, WT, and EEE T cells. PCR primers and probes 
were designed to amplify total HIV-1 DNA after the second template 
switch of reverse transcription (so-called late reverse transcription 
or LRT products) and nuclear DNA subsets that included two-long 
terminal repeat (2-LTR) containing circles and integrated proviruses. 
Figure 5.  Effects of mutations on protein binding and IN strand transfer activity. (a) IN-LEDGF/p75 binding as assessed by Ni-nitrilotriacetic acid pull-
down. Lanes 1–6 show 100% of the levels of input proteins. Pull-down reactions with WT LEDGF/p75 were loaded in lanes 7–11, whereas parallel 
reactions with EEE LEDGF/p75 were analyzed in lanes 12–16. IN was omitted from the reactions loaded in lanes 11 and 16. The gel was stained with 
Coomassie blue. (b) Quantitation of WT and EEE LEDGF/p75 recovery by the indicated IN protein for two experiments, expressed as averages ± SEM. 
The results were normalized to the level of WT LEDGF/p75 recovery by WT IN (set to 100%). (c) IN strand transfer activities. The migration positions of the 
oligonucleotide viral DNA substrate, supercoiled (s.c.) and open circular (o.c.) forms of pGEM-3 target DNA plasmid, as well as half-site and concerted 
integration reaction products, are shown alongside the agarose gel image. IN was omitted from the reaction loaded in lane 1. (d) Quantitation of 
concerted integration activities of IN mutant proteins in the presence of WT or EEE LEDGF/p75. The results (averages ± SEM for n = 2 experiments) were 
normalized to the level of WT IN activity in the presence of WT LEDGF/p75, which was set to 100%. EEE, K401E/K402E/R405E; IN, integrase; LEDGF, lens 
epithelium–derived growth factor; WT, wild type.
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DNA was isolated from cells at 8, 24, and 48 hour postinfection, cor-
responding to the peaks of WT HIV-1 LRT, 2-LTR circle, and provirus 
formation, respectively.32,33
WT LEDGF/p75 expression in this series of experiments 
boosted HIV-Luc infection of TL3 cells ~27-fold, while EEE expres-
sion enhanced RR and RRE transduction ~14- and 9-fold over the 
levels supported by WT LEDGF/p75 (Figure 6a). As expected,10,27 
WT HIV-1 DNA synthesis was independent of the level of LEDGF/
p75 expression (Figure 6b). By contrast, the RR and K42E IN muta-
tions caused approximately three- to fivefold reverse transcription 
defects. Because mutations in IN can affect HIV-1 replication at 
multiple steps, we previously established a classification system to 
delineate those mutations that specifically affect integration (class 
I) from those that additionally affect other steps in the viral life cycle 
(class II).34 The most common pleiotropic defect among class II HIV-1 
IN mutant viruses is reverse transcription, and K42E and RR were 
accordingly typed as class II IN mutant viruses. Combining the K42E 
and RR mutations interestingly restored IN mutant reverse tran-
scription to ~70% of the level of WT HIV-Luc (Figure 6b).
Perturbation of HIV-1 integration through class I IN mutations,35,36 
IN strand transfer inhibitors,37 or depletion of integration cofac-
tors10,27 yields transient increases in the levels of nuclear side-
product DNAs such as 2-LTR circles, and WT HIV-Luc 2-LTR circles 
were accordingly increased by ~2.4-fold in TL3 cells from the level 
observed in WT LEDGF/p75-expressing cells (Figure 6c). Because 
the levels of IN mutant RRE 2-LTR circles were similar to the level 
for WT HIV-Luc in WT LEDGF/p75-expressing cells, the mutant viral 
DNA efficiently accessed cell nuclei. The integration of RRE viral 
DNA, however, strictly depended on the presence of the reverse-
charge EEE LEDGF/p75 cofactor (Figure 6d).
DISCUSSION
Although retroviruses are among the most popular vehicles for 
introducing transgenes, adverse genotoxic effects from inser-
tional mutagenesis are a significant cause for concern in human 
gene therapy (reviewed in ref. 38). Vectors derived from lentiviruses 
such as HIV-1 appear less genotoxic than γ-retroviral predecessors, 
which likely reflects the differential targeting of host cell chroma-
tin by these two types of retroviruses.6,38 Despite this benefit, the 
observed growth advantage of particular cell clones reveals that 
lentiviral vectors, though likely safer than γ-retroviral–based coun-
terparts, may not be free of insertion-based side effects.39 Various 
approaches are being used to increase the safety of lentiviral gene 
therapy vectors, including the modification of cis-acting elements 
to reduce the potential for read-through transcription of growth-
promoting cellular genes.40 Alteration of the sites of DNA inte-
gration is another strategy to increase the safety of gene therapy 
vectors. Modification of HIV-1 IN with site-specific DNA binding 
elements can provide up to an ~10-fold increase in integration site 
preference, but with a concomitant ~10-fold decrease in vector 
titer.5 Global integration retargeting through heterologous CBDs 
fused to the lentivirus- specific targeting host factor LEDGF/p75 IBD 
can by contrast proceed without significant loss in virus titer15–17 and 
reveal novel, genome-wide regions of CBD binding.18 Attempts to 
Figure 6.  WT and IN mutant viral reverse transcription and integration activities. (a) Levels of WT, RR, K42E, and RRE HIV-Luc infectivity using the indicated 
T-cell line. Results were normalized to the level of WT HIV-Luc transduction in the presence of WT LEDGF/p75, which was set to 100%. (b) Levels of LRT 
product formation from the infections in panel a, normalized to the level of WT HIV-Luc DNA synthesis in cells expressing WT LEDGF/p75 (set at 100%). 
(c) Levels of 2-LTR circle formation from panel a infections, normalized to the WT virus in cells expressing WT LEDGF/p75. (d) Virus integration levels 
were normalized to the level of WT HIV-Luc virus in cells expressing WT LEDGF/p75, which was set at 100%. Values in panels a–d represent averages ± 
SD for two independent experiments. Panel a and d statistical comparisons evaluate RR versus RRE virus in EEE LEDGF/p75-expressing cells, whereas 
those in panels c and d compare the activities of the indicated viruses across cell lines. *P < 0.05; **P < 0.01. EEE, K401E/K402E/R405E; IN, integrase; 
LEDGF, lens epithelium–derived growth factor; NS, not significant; WT, wild type.
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utilize heterologous LEDGF/p75 fusion proteins in the clinical set-
ting must circumvent the relatively high copy number of endog-
enous LEDGF/p75 protein in target cells.20 We previously developed 
defective IN mutant viruses whose transduction efficiencies were 
restored to ~13% of maximum in the face of a complementary, 
reverse-engineered LEDGF/p75 mutant protein.21 In this report, we 
have increased the efficiency of this system to ~75% of the level of 
unmodified virus in cells that express WT LEDGF/p75 protein.
The importance of the K42E gain-of-function mutation is evident 
by its independent selection through the serial passage of defec-
tive IN mutant viruses RR and KR in LEDGF/p75 EEE-expressing cells 
(Figures 3 and 4). Strikingly, the K42E mutation by itself reduced 
HIV-1 titer ~7- to 10-fold (Figures 4c and 6a), which is primarily attrib-
utable to a reverse transcription defect (Figure 6b). The inability for 
EEE LEDGF/p75 to support K42E IN strand transfer activity in vitro 
(Figure 5) likely accounts for the added K42E IN mutant viral defect 
in EEE-expressing cells. Although we previously described the selec-
tion of a second-site HIV-1 IN mutation (T125A) that restored func-
tion to replication-defective P109S mutant virus, the T125A change 
on its own conferred no obvious growth disadvantage.41 The K42E 
mutation to the best of our knowledge is the first example of an 
HIV-1 IN gain-of-function mutation that by itself severely limits virus 
activity, though we do note the description of pleiotropic gain-of-
function mutations in other biological systems.42
The K42E mutation impressively boosted the level of RR IN mutant 
reverse transcription, from ~20 to ~70% of the WT, even though 
the change on its own conferred an approximately fivefold reverse 
transcription defect (Figure 6b). As the reverse transcription boost is 
LEDGF/p75 independent, we envisage it in large part drives the gain 
in IN mutant function in the face of WT LEDGF/p75; it is noteworthy 
that this effectively caps the specificity of the RRE virus for EEE over WT 
LEDGF/p75 at approximately three- (Figure 4c) to ninefold (Figure 6a). 
This degree of selectivity is nevertheless predicted to significantly 
improve the efficiency of LEDGF-based retargeting strategies in cells 
that express the endogenous integration cofactor.15,17,43 Because the 
RRE mutant virus integrated in cells that express LEDGF/p75 EEE at 
~70% of the efficiency of WT HIV-1 in WT LEDGF/p75-expressing cells 
(Figure 6d), we conclude that the RRE virus integrates with the WT 
efficiency under these conditions. The ~30% impairment in IN mutant 
RRE reverse transcription would seem to uniquely limit the transduc-
tion efficiency of the optimized IN-LEDGF/p75 reverse-charge system 
(Figure 6).
HIV-1 IN and reverse transcriptase (RT) proteins can interact in 
vitro, with the IN C-terminal domain harboring key RT-interacting 
residues.44 It is unclear how changes in the IN NTD might disrupt and 
then functionally restore reverse transcription, though long-range 
effects of the mutations on RT-IN binding seems one possibility. The 
molecular basis for the integration gain-of-function phenotype was 
investigated by analyzing the position of the Lys42 side chain in 
HIV-1 IN crystal structures. Because the two-domain NTD-CCD con-
struct from the IBD cocrystal structure was based on HIV-2 IN,21 a 
molecular model was constructed by aligning the common CCD ele-
ment from the HIV-1 IN CCD-LEDGF/p75 structure25 with an HIV-1 IN 
NTD-CCD two-domain structure.45 As anticipated21 (Figure 1a), HIV-1 
IN residues Asp6, Glu10, and Glu13 approach LEDGF/p75 residues 
Lys401, Lys402, and Arg405 in the overlay. Lys42 interacts intramo-
lecularly with CCD residue Asp167, which forms part of the critical 
α4/5 connector (IN residues 166-171) engaged by LEDGF/p75 resi-
due Asp366 (ref. 25) (Figure 7). As numerous changes in α4/5 con-
nector residues affect the HIV-1 IN-LEDGF/p75 interaction,26,46,47 we 
speculate that altered connector loop position could determine the 
influence of the K42E mutation on the virus–host interaction. We 
also note that IBD engagement shifts the position of the Asp167 car-
boxylate toward LEDGF/p75 residue Lys360 (Figure 7). It, therefore, 
seems possible that the K42E mutation could influence the protein 
interaction through altering the Asp167-Lys360 contact. Because 
our data emphasizes the benefit of the K42E mutation in the back-
drop of reverse-charge substitutions at multiple other LEDGF/p75 
and IN positions, additional structural work with K42E IN mutant 
proteins will be required to fully appreciate the molecular basis of 
the integration gain-of-function phenotype. We note that structural 
analysis of HIV-2 IN might be of limited benefit, as the analogous 
position 42 amino acid, glutamine, is not positioned to interact with 
Glu167 in the NTD-CCD–IBD cocrystal structure (not shown).
Although site-specific integration has yet to be reported using 
LEDGF/p75 fusion constructs, HIV-1 vectors directed to integrate 
into heterochromatin via HP1α15,16 or CBX117,43 CBDs express remark-
ably well considering overall random targeting of genes and pro-
moter regions. Heterochromatin-directed retargeting is, therefore, 
one potential avenue toward safety-improved lentiviral vectors. 
Retargeting, by definition, requires the presence of the LEDGF/p75 
fusion protein in target cells, which has been accomplished ex vivo 
through transient or stable expression.15–18,43 Results of preliminary 
experiments suggest that piggy backing LEDGF/p75 into the virion 
through its fusion with the viral Vpr accessory protein fails to effec-
tively complement the infection defect of mouse knockout MEFs, 
so this strategy seems unlikely to work. Potential translational appli-
cations are accordingly currently limited to ex vivo settings, and 
Figure 7.  Potential impact of the K42E mutation on reverse-charge HIV-1 
IN and LEDGF/p75 function. The CCD (blue) from molecule A of the HIV-1 
IN CCD-LEDGF/p75 IBD cocrystal structure (protein database code 2bj4)25 
was aligned with the CCD (cyan) of molecule B from the HIV-1 NTD-CCD 
2-domain structure (pdb code 1k6y)45 using PyMOL. Distances of ≤4.0 Å 
between Lys42, Asp167, and Lys360 side chains in the two structures are 
indicated by dashed lines. The CCD α4/5 connector (IN residues 166–171) 
is highlighted in yellow; other coloring is the same as in Figure 1. CCD, 
catalytic core domain; HIV-1, human immunodeficiency virus type 1; 
IBD, IN-binding domain; IN, integrase; LEDGF, lens epithelium–derived 
growth factor; NTD, N-terminal domain.
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heterochromatin-based retargeting through transient expression of 
CBX1-LEDGF from electroporated RNA has been shown to restore 
NADPH-oxidase activity in a cell line model.43 The incorporation of 
components from our optimized reverse-charge HIV-1 IN-LEDGF/p75 
system would be expected to increase the specificity of not only tar-
geted integration under similar translational settings, but also high-
resolution HIT-Seq maps in cells that express endogenous LEDGF/p75 
protein.
MATeRIAlS AND MeTHODS
DNA constructs 
Plasmids pNL43/XmaI, pUC19.2LTR, pNLX.Luc.R−,31 pCG-VSV-G, pCG-gagpol, 
pIRES2-eGFP, pIRES2-eGFP-LEDGF-HA,10 pKBIN6Hthr,48 and pFT-1-LEDGF19 
were previously described. Plasmid pLPCX-HA-LEDGF/p75 was built by 
inserting PCR-amplified HA-LEDGF/p75 into pLPCX vector DNA (Clontech 
Laboratories, Mountain View, CA). Mutations were introduced by PCR using 
Pfu Ultra DNA polymerase (Agilent Technologies, Santa Clara, CA), and 
plasmids were sequenced to verify the presence of mutations and absence 
of unwanted secondary changes.
Cells, viruses, and infection assays 
HEK293T and MEF cells were grown in Dulbecco’s modified Eagle medium 
supplemented to contain 10% fetal bovine serum and 100 IU/ml penicillin–
streptomycin. SupT1 and TL3 cells were maintained in Roswell Park 
Memorial Institute 1640 medium containing 10% fetal bovine serum and 
100 IU/ml penicillin–streptomycin. Reexpression of LEDGF/p75 in TL3 cells 
was accomplished by transduction with pLPCX-HA-LEDGF/p75 expression 
vectors that carried shRNA-resistant complementary DNAs with seven 
synonymous changes within the 21-nt shRNA target region. Vectors were 
produced in HEK293T cells by transfecting 10 µg pLPCX-HA-LEDGF/p75, 3 
µg pCG-gagpol, and 3 µg pCG-VSV-G using Fugene (Promega Corporation, 
Madison, WI). Supernatants collected 24 and 48 hours after transfection 
were concentrated 20-fold by ultracentrifugation at 150,000 g for 3 hours 
at 4 °C. TL3 cells (1 × 105) were transduced with concentrated supernatants, 
followed by the addition of puromycin (0.15 µg/ml) 48 hours later. Cells were 
seeded for single-cell cloning 48 hours thereafter. Western blotting was 
performed as previously described.10,13
HIV-1NL4-3 viruses were generated by cotransfecting HEK293T cells with 
pNLX.Luc.R− and pCG-VSV-G (single-round HIV-Luc) or pNL43/XmaI (repli-
cation competent) as previously described; levels of virus release into the 
cell supernatant were determined by exogenous RT assay.31 SupT1 (1 × 105 
per well of a 24-well plate) were infected in duplicate with equal RT-cpm 
(2.5 × 106) of WT or IN mutant HIV-Luc for 2 hours. Cells harvested 48 hours 
from the start of infection were processed for luciferase activity assays in 
duplicate, and results were processed as average relative light units per 
total microgram protein in cell extracts as determined by Bradford assay 
(Bio-Rad Laboratories, Hercules, CA).31 SupT1 cells (106) were infected 
with equal RT-cpm (106) of WT or IN mutant HIV-1NL4-3. MEF cells (5 × 10
6) 
were transfected with 10 µg of pIRES2-eGFP expression vector using MEF 
Nucleofector solution 1 (Lonza, Allendale, NJ) according to the manufactur-
er’s instructions. Transfected cells were plated in 10-cm dishes for 24 hours 
prior to fluorescence-activated cell sorting to select for green fluorescent 
protein–positive transfectants. After sorting, cells (2 × 104) were seeded in 
wells of a 24-well plate prior to infection with equal RT-cpm (106) of WT 
or IN mutant HIV-Luc in duplicate. Relative light units per total microgram 
protein values from cells transfected with empty vector pIRES2-eGFP were 
subtracted from experimental samples.10,13
Recombinant proteins and in vitro biochemistry 
His6-tagged HIV-1 IN proteins were expressed from pKBIN6Hthr in E. coli 
and purified as previously described.49 LEDGF/p75 proteins expressed from 
pFT-1-LEDGF in bacteria were purified as described.19 His6 tag was removed 
from IN by cleavage with thrombin before activity assays, and conditions 
for the Ni-nitrilotriacetic acid pull-down and IN strand transfer assays were 
as described.49
Quantification of HIV-1 reverse transcription and integration
 SupT1 cells were washed following 2 hours of infection with DNase-treated 
HIV-Luc, and DNA was isolated from cells using the DNeasy blood and 
tissue kit (Qiagen, Germantown, MD). HIV-1 LRT products were amplified in 
duplicate reactions containing 20–30 ng of DNA, 0.2 µmol/l primers AE2963/
AE4422, 0.1 µmol/l probe AE2965, and 1 × QuantiTect Probe PCR Master 
Mix. Reactions were incubated at 50 °C for 2 minutes, 95 °C for 15 minutes, 
and then cycled 40 times at 94 °C for 15 seconds, 58 °C for 30 seconds, and 
72 °C for 30 seconds. Serial dilutions of pNLX.luc.R− in uninfected cell DNA 
generated the LRT standard curve. The same amplification conditions were 
used for 2-LTR circles with primers AE4450/AE4451 and probe AE4452; serial 
dilution of plasmid pUC19.2LTR in uninfected cell DNA generated the 2-LTR 
circle standard curve.10,32,50 Integration efficiency was quantitated by Alu-PCR 
as previously described.50 First-round PCRs amplified sequences between 
integrated virus and chromosomal Alu elements using primers AE3014/
AE1066 at 94 °C for 5 minutes, followed by 18 cycles of 30 seconds at 94 °C, 30 
seconds at 60 °C, and 5 minutes at 70 °C; reactions were terminated following 
a final 10-minute extension at 72 °C. Second-round DNA (1–2 µl) amplification 
utilized primers AE3013/AE990 and probe AE995 under the aforementioned 
quantitative PCR cycling conditions. Values obtained from parallel first-round 
reactions that omitted Alu-specific AE1066 primer were subtracted from 
second-round quantitative PCR values. The Alu-PCR standard curve was made 
by step-wise dilution of DNA from WT HIV-Luc-infected cells in uninfected 
cell DNA. To account for potential plasmid DNA carryover from transfected 
cell supernatants, parallel infections were conducted in the presence of RT 
inhibitors (100 µmol/l azidothymidine or 10 µmol/l efavirenz), and resulting 
quantitative PCR values were subtracted from experimental LRT, 2-LTR circle, 
and Alu integration samples.
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